Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Hematological malignancy Stories

2013-06-05 12:31:36

June 5 - June 25 campaign to help in the fight against blood cancer SAN BERNARDINO, Calif., June 5, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society is teaming up once again with Stater Bros. Charities for the sixth year of The Leukemia & Lymphoma Society's "Light The Night" fundraising campaign to raise awareness and funds for Leukemia, Hodgkin and Non-Hodgkin Lymphoma, Myeloma and Myelodysplastic Syndromes. (Logo:...

2013-06-03 12:29:27

Data in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma NORTH CHICAGO, Ill., June 3, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from a Phase I study of ABT-199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL), the most common leukemia in the United States, and relapsed/refractory non-Hodgkin's lymphoma (NHL)....

2013-04-08 08:29:37

SUNNYVALE, Calif., April 8, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that the U.S. Food and Drug Administration (FDA) has granted an additional Breakthrough Therapy Designation for the investigational oral agent ibrutinib as monotherapy for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients with deletion of the short arm of chromosome 17 (deletion 17p). Patients harboring a deletion within chromosome 17 generally...

2013-04-05 16:23:26

A Live Telephone/Web Education Program Offering Live Spanish Interpretation Featuring International CML Expert Jorge Cortes, MD WHITE PLAINS, N.Y., April 5, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is committed to bringing the most current information about blood cancers to all patients and is pleased to announce a unique educational opportunity for Spanish-speaking patients with chronic myeloid leukemia (CML). On Wednesday, April 17, from 1:00 to 2:00 PM Eastern...

2013-04-04 16:23:50

WHITE PLAINS, N.Y., April 4, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is the world's largest voluntary health agency funding many of today's breakthroughs in blood cancer treatments, including advances in targeted therapies, immunotherapies and epigenetics. Many LLS-funded researchers will be presenting results of some of their latest work at the 104(th) AACR Annual Meeting 2013, taking place at the Walter E. Washington Convention Center in Washington. D.C., April...

2013-03-21 16:25:37

Two, 10-week fundraising campaigns supporting LLS's vision of a world without blood cancer will kick off in April SAN FRANCISCO, March 21, 2013 /PRNewswire-USNewswire/ -- The Greater Bay Area chapter of The Leukemia & Lymphoma Society (LLS) will launch its 23(rd) annual San Francisco Man & Woman of the Year fundraising campaign on April 4, 2013 at the University Club in San Francisco and its inaugural North Bay Man & Woman of the Year campaign on April 18, 2013 at a...

2013-03-21 14:58:25

Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, or acute myeloid leukemia resulting from MDS and have failed treatment with azanucleosides. The therapy may not be effective for all patients, but those with trisomy 8 chromosomal disorder have higher rates of stable disease and respond better to treatment with dasatinib,...

2013-03-04 04:21:27

SEATTLE, March 4, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) and Chroma Therapeutics Ltd. announced today that Lancet Oncology has published results from the OPAL Phase 2 study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML). Tosedostat is an oral aminopeptidase inhibitor which has been shown to deprive tumor cells of the amino acid building blocks they need to make proteins necessary for tumor cell survival. The lead...

2013-02-28 16:27:36

WHITE PLAINS, N.Y., Feb. 28, 2013 /PRNewswire/ -- Medical innovation and sustained research investment are dramatically transforming the landscape in blood cancers. To that end, The Leukemia & Lymphoma Society (LLS) continues to drive a progressive research agenda to improve outcomes for patients who urgently need new therapies. Today LLS announced it has identified three priority areas toward which it will direct new funding. LLS has issued a request for proposals - entitled "Quest for...

2013-02-22 12:23:03

500th XF Data Reference in Elsevier: Cell Stem Cell BILLERICA, Mass., Feb. 22, 2013 /PRNewswire/ -- Seahorse Bioscience, the leader in instruments and assay kits for measuring cell metabolism, announced a new milestone: the 500(th) journal reference including XF assay data. The paper, titled BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells, will be published in the March 7, 2013 issue of the journal Cell Stem Cell....